0,1,2,3,4,5,6,7,8
,Table 3 Distribution of medical conditions for confirmed outpatient cases and negative controls according to age group,,,,,,,
,,,0-4 years,,,,5-17 years,
,Cases,Controls,Crude OR,P value,Cases,Controls,Crude OR,P value
,(n = 122),(n = 122),(95 % CI),,(n = 93),(n = 93),(95 % CI),
Pneumonia in previous 2 years,12 (9.8 %),2 (1.6 %),6.00 (1.34 – 26.81),0.02,8 (8.6 %),6 (6.5 %),1.48 (0.47 – 4.70),0.50
Asthma,10 (8.2 %),4 (3.3 %),3.00 (0.81 – 11.08),0.10,16 (17.2 %),9 (9.7 %),2.07 (0.83 – 5.15),0.12
Renal failure or nephritic,1 (0.8 %),0 (0.0 %),-,-,3 (3.2 %),2 (2.2 %),1.50 (0.25 – 8.98),0.66
syndrome,,,,,,,,
Diabetes,0 (0.0 %),0 (0.0 %),-,-,1 (1.1 %),2 (2.2 %),0.50 (0.04 – 5.51),0.57
Disabling neurological disease,1 (0.8 %),3 (2.4 %),0.33 (0.03 – 3.20),0.34,6 (6.5 %),0 (0.0 %),65.29(0.09– 46313),0.21
Transplantation,0 (0.0 %),0 (0.0 %),-,-,4 (4.3 %),0 (0.0 %),65.29 (0.02 – 202501.6),0.31
Obesity,0 (0.0 %),1 (1.1 %),-,-,2 (2.6 %),2 (2.6 %),0.01 (0 – 500061.3),0.58
Previous antibiotics,18 (14.8 %),27 (22.0 %),0.50 (0.22 – 1.11),0.09,9 (9.7 %),11 (11.8 %),0.83 (0.33 – 2.11),0.69
Systemic corticosteroids,4 (3.3 %),1 (0.8 %),4.00 (0.45 – 35.79),0.21,5 (5.4 %),2 (2.2 %),4.70 (0.52 – 42.78),0.17
Inhaled corticosteroids,13 (10.7 %),7 (5.7 %),2.20 (0.76 – 6.33),0.14,7 (7.5 %),5 (5.4 %),1.40 (0.44 – 4.41),0.57
≥1 risk factors,16 (13.1 %),12 (9.8 %),1.50 (0.61 – 3.67),0.37,29 (31.2 %),18 (19.4 %),1.97 (0.97 – 3.96),0.06
≥2 risk factors,1 (0.8 %),2 (1.6 %),0.50 (0.04 – 5.51),0.57,6 (6.5 %),1 (1.1 %),6.77 (0.81 – 56.84),0.08
